Mark A Rubin

List of Publications by Year
in descending order

498 papers	85,274 citations	369 135 h-index	421 276 g-index
531 all docs	531 docs citations	531 times ranked	66234 citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent Fusion of <i>TMPRSS2</i> and ETS Transcription Factor Genes in Prostate Cancer. Science, 2005, 310, 644-648.	12.6	3,541
2	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	27.8	3,331
3	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660
4	The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002, 419, 624-629.	27.8	2,411
5	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
6	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 2013, 31, 1023-1031.	17.5	1,785
7	Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412, 822-826.	27.8	1,551
8	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11606-11611.	7.1	1,482
9	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 2005, 436, 117-122.	27.8	1,329
10	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics, 2012, 44, 685-689.	21.4	1,300
11	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	27.0	1,205
12	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305.	30.7	1,193
13	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	28.9	1,184
14	The genomic complexity of primary human prostate cancer. Nature, 2011, 470, 214-220.	27.8	1,107
15	Punctuated Evolution of Prostate Cancer Genomes. Cell, 2013, 153, 666-677.	28.9	1,107
16	Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898.	27.8	1,020
17	Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer. Cancer Research, 2006, 66, 2815-2825.	0.9	967
18	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20007-20012.	7.1	927

#	Article	IF	Citations
19	High-throughput oncogene mutation profiling in human cancer. Nature Genetics, 2007, 39, 347-351.	21.4	927
20	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 2009, 41, 1238-1242.	21.4	862
21	Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436.	7.1	839
22	Integrative molecular concept modeling of prostate cancer progression. Nature Genetics, 2007, 39, 41-51.	21.4	837
23	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. Cancer Research, 2004, 64, 9209-9216.	0.9	816
24	Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. Cell, 2009, 138, 245-256.	28.9	797
25	<i>SOX2</i> promotes lineage plasticity and antiandrogen resistance in <i>TP53</i> - and <i>RB1</i> -deficient prostate cancer. Science, 2017, 355, 84-88.	12.6	759
26	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 2007, 448, 595-599.	27.8	743
27	Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine. Cancer Discovery, 2017, 7, 462-477.	9.4	735
28	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 2005, 8, 393-406.	16.8	731
29	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	9.4	725
30	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	5.3	608
31	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	21.4	601
32	Autoantibody Signatures in Prostate Cancer. New England Journal of Medicine, 2005, 353, 1224-1235.	27.0	581
33	Î±-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 1662.	7.4	565
34	Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Research, 2004, 64, 2270-2305.	0.9	530
35	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature Communications, 2014, 5, 5383.	12.8	522
36	Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Research, 2002, 62, 4427-33.	0.9	511

#	Article	IF	Citations
37	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	1.9	488
38	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	1.6	477
39	Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature, 2018, 560, 499-503.	27.8	477
40	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Research, 2006, 66, 8337-8341.	0.9	475
41	Novel <i>YAP1â€TFE3</i> fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes and Cancer, 2013, 52, 775-784.	2.8	463
42	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. American Journal of Surgical Pathology, 2014, 38, 756-767.	3.7	439
43	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	30.7	436
44	TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer. Cancer Research, 2006, 66, 3396-3400.	0.9	432
45	Analyses of non-coding somatic drivers in 2,658Âcancer whole genomes. Nature, 2020, 578, 102-111.	27.8	424
46	Role of non-coding sequence variants in cancer. Nature Reviews Genetics, 2016, 17, 93-108.	16.3	420
47	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. Journal of Cellular Biochemistry, 2003, 89, 462-473.	2.6	405
48	TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion. American Journal of Surgical Pathology, 2007, 31, 882-888.	3.7	394
49	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577.	16.8	394
50	Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology, 2007, 38, 696-701.	2.0	388
51	Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity. European Urology, 2013, 63, 920-926.	1.9	379
52	Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. Science Translational Medicine, 2012, 4, 127rv3.	12.4	378
53	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. Cancer Research, 2009, 69, 4674-4681.	0.9	370
54	Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody. American Journal of Surgical Pathology, 2009, 33, 984-991.	3.7	364

#	Article	IF	Citations
55	Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics. Science, 2013, 342, 1235587.	12.6	341
56	Aggressive Variants of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 2846-2850.	7.0	339
57	ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. European Urology, 2009, 56, 275-286.	1.9	332
58	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. Journal of Clinical Oncology, 2009, 27, 3459-3464.	1.6	329
59	Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma. Science Translational Medicine, 2011, 3, 98ra82.	12.4	328
60	Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease. Cancer Research, 2009, 69, 5601-5609.	0.9	325
61	E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Research, 2003, 5, R217-22.	5.0	323
62	Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease. American Journal of Pathology, 2012, 181, 1573-1584.	3.8	321
63	Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and Modalities. Journal of Urology, 2007, 178, 2260-2267.	0.4	317
64	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS ONE, 2009, 4, e7887.	2.5	316
65	Urine <i>TMPRSS2:ERG</i> Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Science Translational Medicine, 2011, 3, 94ra72.	12.4	313
66	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. Cancer Research, 2004, 64, 6854-6857.	0.9	310
67	Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis. Cancer Research, 2005, 65, 5561-5570.	0.9	309
68	Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia, 2010, 12, 590-IN21.	5.3	305
69	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. Cancer Research, 2014, 74, 1272-1283.	0.9	304
70	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	16.8	303
71	Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis. American Journal of Surgical Pathology, 2002, 26, 312-319.	3.7	294
72	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2008, 100, 815-825.	6.3	286

#	Article	IF	Citations
73	The Master Neural Transcription Factor BRN2 Is an Androgen Receptorâ€“Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery, 2017, 7, 54-71.	9.4	285
74	AlleleSeq: analysis of alleleâ€specific expression and binding in a network framework. Molecular Systems Biology, 2011, 7, 522.	7.2	284
75	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology, 2007, 20, 538-544.	5.5	281
76	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
77	Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discovery, 2017, 7, 736-749.	9.4	275
78	Alpha-Methylacyl-CoA Racemase. American Journal of Surgical Pathology, 2002, 26, 926-931.	3.7	274
79	Common Gene Rearrangements in Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 3659-3668.	1.6	268
80	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	7.1	264
81	Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature Genetics, 2016, 48, 1490-1499.	21.4	250
82	Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 661-668.	6.3	249
83	Characterization of <i>TMPRSS2</i>-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Research, 2008, 68, 3584-3590.	0.9	249
84	Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404.	12.8	246
85	Prostate cancerâ€“associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	30.7	240
86	<i>TMPRSS2â€“ERG</i> gene fusion prevalence and class are significantly different in prostate cancer of caucasian, africanâ€american and japanese patients. Prostate, 2011, 71, 489-497.	2.3	239
87	<i>PCAT-1</i>, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. Cancer Research, 2014, 74, 1651-1660.	0.9	237
88	EML4-ALK Fusion Lung Cancer: A Rare Acquired Event. Neoplasia, 2008, 10, 298-302.	5.3	231
89	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Medical Genomics, 2010, 3, 8.	1.5	219
90	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports, 2015, 12, 922-936.	6.4	216

#	Article	IF	Citations
91	Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer. Neoplasia, 2006, 8, 885-888.	5.3	212
92	Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6997-7002.	7.1	210
93	Prevalence of <i>TMPRSS2-ERG</i> Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. Clinical Cancer Research, 2009, 15, 4706-4711.	7.0	205
94	Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer. Neoplasia, 2013, 15, 1-IN4.	5.3	205
95	Renal Oncocytosis. American Journal of Surgical Pathology, 1999, 23, 1094.	3.7	204
96	The Mutational Landscape of Prostate Cancer. European Urology, 2013, 64, 567-576.	1.9	203
97	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer Research, 2005, 65, 1213-1222.	0.9	202
98	Characterization of <i>TMPRSS2-ERG</i> Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. Clinical Cancer Research, 2008, 14, 3380-3385.	7.0	200
99	Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science, 2014, 346, 85-89.	12.6	200
100	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	7.0	200
101	Biology and evolution of poorly differentiated neuroendocrine tumors. Nature Medicine, 2017, 23, 664-673.	30.7	192
102	Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy. Cancer Research, 2009, 69, 4434-4442.	0.9	190
103	Recurrent <i>NCOA2</i> gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes and Cancer, 2013, 52, 538-550.	2.8	189
104	Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nature Biotechnology, 2017, 35, 577-582.	17.5	188
105	Characterization of RhoC Expression in Benign and Malignant Breast Disease. American Journal of Pathology, 2002, 160, 579-584.	3.8	187
106	Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer. Journal of Clinical Oncology, 2012, 30, e386-e389.	1.6	185
107	Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer. Clinical Cancer Research, 2009, 15, 5794-5802.	7.0	184
108	SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformationâ€"Specific Fusion Transcript in Prostate Cancer. Cancer Research, 2009, 69, 2734-2738.	0.9	181

#	Article	IF	Citations
109	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 566-571.	1.6	181
110	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Research, 2011, 21, 56-67.	5.5	179
111	SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Modern Pathology, 2011, 24, 944-953.	5.5	177
112	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51.	7.0	177
113	Neuroendocrine expression in metastaticprostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Human Pathology, 2000, 31, 406-414.	2.0	176
114	Comparison of the Basal Cell-Specific Markers, 34Î²E12 and p63, in the Diagnosis of Prostate Cancer. American Journal of Surgical Pathology, 2002, 26, 1161-1168.	3.7	175
115	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Human Molecular Genetics, 2004, 13, 1303-1313.	2.9	171
116	DNA Repair in Prostate Cancer: Biology and Clinical Implications. European Urology, 2017, 71, 417-425.	1.9	169
117	DNA Unwinding by ASCC3 Helicase Is Coupled to ALKBH3-Dependent DNA Alkylation Repair and Cancer Cell Proliferation. Molecular Cell, 2011, 44, 373-384.	9.7	166
118	Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics, 2013, 45, 1428-1430.	21.4	164
119	Dysregulation of the Annexin Family Protein Family Is Associated with Prostate Cancer Progression. American Journal of Pathology, 2003, 162, 255-261.	3.8	162
120	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Journal of Pathology, 2012, 227, 286-297.	4.5	161
121	E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. Human Pathology, 2001, 32, 690-697.	2.0	159
122	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 4441-4453.	8.2	155
123	APC/CTNNB1 (?-catenin) pathway alterations in human prostate cancers. Genes Chromosomes and Cancer, 2002, 34, 9-16.	2.8	152
124	SPOP Mutation Drives Prostate Tumorigenesis InÂVivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell, 2017, 31, 436-451.	16.8	152
125	Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression. Cancer Research, 2013, 73, 1232-1244.	0.9	150
126	SPOP mutation leads to genomic instability in prostate cancer. ELife, 2015, 4, .	6.0	148

#	Article	IF	Citations
127	The Role of Calpain in the Proteolytic Cleavage of E-cadherin in Prostate and Mammary Epithelial Cells. Journal of Biological Chemistry, 2003, 278, 1372-1379.	3.4	146
128	TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications. Urology, 2007, 70, 630-633.	1.0	146
129	Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer. Cancer Research, 2004, 64, 3814-3822.	0.9	145
130	Quantitative Determination of Expression of the Prostate Cancer Protein Î±-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA). American Journal of Pathology, 2004, 164, 831-840.	3.8	145
131	SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. Neoplasia, 2014, 16, 14-W10.	5.3	145
132	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	2.5	143
133	Oncogene-mediated alterations in chromatin conformation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9083-9088.	7.1	142
134	Basal Cell Cocktail (34Î²E12 + p63) Improves the Detection of Prostate Basal Cells. American Journal of Surgical Pathology, 2003, 27, 365-371.	3.7	141
135	Prevalence of TMPRSS2â€"ERG and SLC45A3â€"ERG gene fusions in a large prostatectomy cohort. Modern Pathology, 2010, 23, 539-546.	5.5	141
136	Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays. PLoS Computational Biology, 2006, 2, e41.	3.2	140
137	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2391-2396.	1.6	140
138	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature Communications, 2019, 10, 2977.	12.8	140
139	Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens. American Journal of Pathology, 2002, 161, 1743-1748.	3.8	138
140	Novel MIR143â€NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes and Cancer, 2013, 52, 1075-1087.	2.8	138
141	FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biology, 2010, 11, R104.	8.8	137
142	Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men. Clinical Cancer Research, 2014, 20, 4925-4934.	7.0	137
143	Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy NaÃ¯ve Men. Journal of Urology, 2015, 194, 65-72.	0.4	137
144	Human prostate sphereâ€forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate, 2010, 70, 491-501.	2.3	130

#	Article	IF	Citations
145	Genome-wide DNA Methylation Events in <i>TMPRSS2â€“ERG</i> Fusion-Negative Prostate Cancers Implicate an EZH2-Dependent Mechanism with <i>miR-26a</i> Hypermethylation. Cancer Discovery, 2012, 2, 1024-1035.	9.4	127
146	The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression. Cancer Research, 2004, 64, 825-829.	0.9	126
147	Postatrophic Hyperplasia of the Prostate Gland. American Journal of Pathology, 2001, 158, 1767-1773.	3.8	125
148	How Well Does the Gleason Score Predict Prostate Cancer Death? A 20-Year Followup of a Population Based Cohort in Sweden. Journal of Urology, 2006, 175, 1337-1340.	0.4	125
149	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123
150	Î±-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation. American Journal of Pathology, 2002, 161, 841-848.	3.8	121
151	Humoral Immune Response to Â-Methylacyl-CoA Racemase and Prostate Cancer. Journal of the National Cancer Institute, 2004, 96, 834-843.	6.3	121
152	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	7.1	120
153	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discovery, 2018, 8, 1632-1653.	9.4	120
154	Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clinical Cancer Research, 2003, 9, 1801-7.	7.0	120
155	Molecular Characterization of TMPRSS2-ERG Gene Fusion in the NCI-H660 Prostate Cancer Cell Line: A New Perspective for an Old Model. Neoplasia, 2007, 9, 200-IN3.	5.3	119
156	Cribriform Carcinoma of the Prostate and Cribriform Prostatic Intraepithelial Neoplasia. American Journal of Surgical Pathology, 1998, 22, 840-848.	3.7	118
157	A Proposal on the Identification, Histologic Reporting, and Implications of Intraductal Prostatic Carcinoma. Archives of Pathology and Laboratory Medicine, 2007, 131, 1103-1109.	2.5	118
158	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	2.5	117
159	The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO Journal, 2007, 26, 4523-4534.	7.8	116
160	Evaluating Localized Prostate Cancer and Identifying Candidates for Focal Therapy. Urology, 2008, 72, S12-S24.	1.0	114
161	ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Modern Pathology, 2010, 23, 1061-1067.	5.5	114
162	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Molecular Cell, 2015, 58, 925-934.	9.7	114

#	Article	IF	Citations
163	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clinical Cancer Research, 2018, 24, 5585-5593.	7.0	113
164	Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells. Cancer Research, 2005, 65, 5750-5760.	0.9	112
165	Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer. Cancer Research, 2012, 72, 616-625.	0.9	111
166	Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent. Cancer Research, 2008, 68, 2286-2291.	0.9	108
167	Profiling and Verification of Gene Expression Patterns in Normal and Malignant Human Prostate Tissues by cDNA Microarray Analysis. Neoplasia, 2001, 3, 43-52.	5.3	107
168	An Oncogenic Role for <i>ETV1</i> in Melanoma. Cancer Research, 2010, 70, 2075-2084.	0.9	107
169	Molecular Profiling and the Identification of Genes Associated With Metastatic Oral Cavity/Pharynx Squamous Cell Carcinoma. JAMA Otolaryngology, 2004, 130, 295.	1.2	106
170	Decreased Î±-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1424-1432.	2.5	105
171	N-myc Downstream Regulated Gene 1 (NDRG1) Is Fused to ERG in Prostate Cancer. Neoplasia, 2009, 11, 804-W18.	5.3	105
172	Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. Cancer Research, 2007, 67, 8229-8239.	0.9	103
173	Prostate Needle Biopsy Reporting. American Journal of Surgical Pathology, 2004, 28, 946-952.	3.7	102
174	Relational Database Structure to Manage High-Density Tissue Microarray Data and Images for Pathology Studies Focusing on Clinical Outcome. American Journal of Pathology, 2001, 159, 837-843.	3.8	100
175	Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer. Cancer Research, 2006, 66, 11897-11906.	0.9	100
176	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European Urology, 2018, 73, 687-693.	1.9	99
177	Clinical significance of TTFâ€1 protein expression and <i>TTFâ€1</i> gene amplification in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1977-1986.	3.6	98
178	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. Journal of Clinical Investigation, 2008, 118, 2711-2721.	8.2	97
179	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood, 2012, 120, 5181-5184.	1.4	96
180	ERG induces taxane resistance in castration-resistant prostate cancer. Nature Communications, 2014, 5, 5548.	12.8	96

#	Article	IF	Citations
181	Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. Human Pathology, 2014, 45, 709-716.	2.0	96
182	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	12.8	96
183	Contemporary Grading for Prostate Cancer: Implications for Patient Care. European Urology, 2013, 63, 892-901.	1.9	95
184	Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function <i>ERF</i> Mutations. Cancer Discovery, 2017, 7, 973-983.	9.4	94
185	Apoptosis and Expression of Bcl-2, Bcl-X_L, and Bax in Renal Cell Carcinomas. Cancer Investigation, 2002, 20, 324-332.	1.3	93
186	Inadequate formalin fixation decreases reliability of p27Kip1 immunohistochemical staining: Probing optimal fixation time using high-density tissue microarrays. Human Pathology, 2002, 33, 756-760.	2.0	92
187	Characterization of <i>KRAS</i> Rearrangements in Metastatic Prostate Cancer. Cancer Discovery, 2011, 1, 35-43.	9.4	91
188	Truncation of the Î²-Catenin Binding Domain of E-cadherin Precedes Epithelial Apoptosis during Prostate and Mammary Involution. Journal of Biological Chemistry, 2000, 275, 3328-3334.	3.4	90
189	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology, 2002, 60, 760-765.	1.0	90
190	Defining Aggressive Prostate Cancer Using a 12-Gene Model. Neoplasia, 2006, 8, 59-68.	5.3	90
191	<i>TMPRSS2:ERG</i> Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia. Journal of Clinical Oncology, 2014, 32, 206-211.	1.6	90
192	Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer. Neoplasia, 2008, 10, 1285-IN35.	5.3	89
193	Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB Journal, 2005, 19, 1-23.	0.5	88
194	The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 513-519.	4.4	88
195	Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology, 1999, 54, 1039-1043.	1.0	86
196	Distinct genomic aberrations associated with <i>ERG</i> rearranged prostate cancer. Genes Chromosomes and Cancer, 2009, 48, 366-380.	2.8	86
197	ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer Disease. Neoplasia, 2006, 8, 319-329.	5.3	85
198	Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358.	8.2	83

#	Article	IF	Citations
199	Usefulness of Basal Cell Cocktail (34Î²E12 + p63) in the Diagnosis of Atypical Prostate Glandular Proliferations. American Journal of Clinical Pathology, 2004, 122, 517-523.	0.7	82
200	Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle, 2008, 7, 2257-2267.	2.6	80
201	Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology, 2014, 15, 439.	8.8	80
202	MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features. Human Pathology, 2014, 45, 2270-2280.	2.0	79
203	PAR1-mediated NFÎºB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. Journal of Cellular Biochemistry, 2005, 96, 641-652.	2.6	78
204	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy, 2009, 8, 2042-2050.	3.4	78
205	Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. Journal of Clinical Investigation, 2002, 110, 351-360.	8.2	78
206	RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease. Neoplasia, 2009, 11, 956-963.	5.3	76
207	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549.	12.8	76
208	Patient-derived xenografts and organoids model therapy response in prostate cancer. Nature Communications, 2021, 12, 1117.	12.8	76
209	Translational Crossroads for Biomarkers. Clinical Cancer Research, 2005, 11, 6103-6108.	7.0	73
210	Pathway and network analysis of more than 2500 whole cancer genomes. Nature Communications, 2020, 11, 729.	12.8	73
211	Early Effects of Castration on the Vascular System of the Rat Ventral Prostate Gland*. Endocrinology, 1999, 140, 1920-1926.	2.8	72
212	Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. , 1998, 35, 95-101.		71
213	Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer. Cancer Research, 2007, 67, 10296-10303.	0.9	71
214	Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight, 2018, 3, .	5.0	71
215	Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Human Pathology, 2004, 35, 1462-1468.	2.0	70
216	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell, 2019, 35, 603-617.e8.	16.8	70

#	Article	IF	Citations
217	Epigenomic Alterations in Localized and Advanced Prostate Cancer. Neoplasia, 2013, 15, 373-IN5.	5.3	69
218	Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene, 2021, 40, 1205-1216.	5.9	69
219	CAN PERINEURAL INVASION ON PROSTATE NEEDLE BIOPSY PREDICT PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY?. Journal of Urology, 1999, 162, 103-106.	0.4	68
220	Tissue Microarray Assessment of Prostate Cancer Tumor Proliferation in African- American and White Men. Journal of the National Cancer Institute, 2000, 92, 937-939.	6.3	68
221	Elevated Î±-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer. American Journal of Pathology, 2004, 164, 787-793.	3.8	68
222	SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Research, 2008, 36, 2446-2456.	14.5	68
223	Testing mutual exclusivity of ETS rearranged prostate cancer. Laboratory Investigation, 2011, 91, 404-412.	3.7	68
224	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. Npj Genomic Medicine, 2016, 1, .	3.8	68
225	Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy. Molecular Cell, 2018, 70, 531-544.e9.	9.7	68
226	Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate, 2000, 43, 278-285.	2.3	67
227	Intravascular Large Cell Lymphoma Coexisting Within Hemangiomas of the Skin. American Journal of Surgical Pathology, 1997, 21, 860-864.	3.7	67
228	NSD2 is a conserved driver of metastatic prostate cancer progression. Nature Communications, 2018, 9, 5201.	12.8	66
229	Activation of Î²-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-Î²-Catenin Interaction. Molecular and Cellular Biology, 2006, 26, 929-939.	2.3	65
230	The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. , 1999, 86, 492-497.		64
231	Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. American Journal of Clinical Pathology, 2003, 120, 737-745.	0.7	64
232	Anatomical retroâ€apical technique of synchronous (posterior and anterior) urethral transection: a novel approach for ameliorating apical margin positivity during robotic radical prostatectomy. BJU International, 2010, 106, 1364-1373.	2.5	64
233	Health: Make precision medicine work for cancer care. Nature, 2015, 520, 290-291.	27.8	64
234	Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer. European Urology, 2016, 69, 557-560.	1.9	64

#	Article	IF	Citations
235	Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate, 1999, 40, 172-177.	2.3	63
236	Relationship and Significance of Greatest Percentage of Tumor and Perineural Invasion on Needle Biopsy in Prostatic Adenocarcinoma. American Journal of Surgical Pathology, 2000, 24, 183-189.	3.7	62
237	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	1.9	62
238	DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns. Cancer Cell, 2019, 35, 297-314.e8.	16.8	62
239	A phase II trial of gefitinib in patients with nonâ€metastatic hormoneâ€refractory prostate cancer. BJU International, 2007, 100, 765-769.	2.5	61
240	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell, 2017, 32, 792-806.e7.	16.8	61
241	Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 595-600.	2.5	60
242	Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas. Diagnostic Molecular Pathology, 2011, 20, 129-137.	2.1	60
243	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	12.8	60
244	The Phosphoinositide Kinase PIKfyve Mediates Epidermal Growth Factor Receptor Trafficking to the Nucleus. Cancer Research, 2007, 67, 9229-9237.	0.9	59
245	Pathway Biomarker Profiling of Localized and Metastatic Human Prostate Cancer Reveal Metastatic and Prognostic Signatures. Journal of Proteome Research, 2009, 8, 3044-3054.	3.7	59
246	The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies With â€œAtypical Glands Suspicious for Cancerâ€• American Journal of Surgical Pathology, 2011, 35, 608-614.	3.7	59
247	Multiphoton microscopy for structure identification in human prostate and periprostatic tissue: implications in prostate cancer surgery. BJU International, 2011, 108, 1421-1429.	2.5	59
248	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. Neoplasia, 2012, 14, 905-IN8.	5.3	59
249	Development of an Integrated Prostate Cancer Research Information System. Clinical Genitourinary Cancer, 2006, 5, 61-66.	1.9	56
250	ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer. Urology, 2010, 75, 762-767.	1.0	56
251	Should a Gleason Score Be Assigned to a Minute Focus of Carcinoma on Prostate Biopsy?. American Journal of Surgical Pathology, 2000, 24, 1634-1640.	3.7	55
252	Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology, 2000, 55, 904-908.	1.0	55

#	Article	IF	Citations
253	Genetic Variation of Genes Involved in Dihydrotestosterone Metabolism and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 229-239.	2.5	55
254	Multiphoton Microscopy in the Evaluation of Human Bladder Biopsies. Archives of Pathology and Laboratory Medicine, 2012, 136, 517-526.	2.5	55
255	Use of fine needle aspiration for solid breast lesions Is accurate and cost-effective. American Journal of Surgery, 1997, 174, 694-698.	1.8	54
256	A hierarchical NaÃ¯ve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays. BMC Bioinformatics, 2006, 7, 514.	2.6	54
257	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience, 2018, 7, .	6.4	54
258	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Molecular Cell, 2020, 80, 562-577.	9.7	54
259	Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. Journal of Clinical Investigation, 2002, 110, 351-360.	8.2	54
260	Web-based tissue microarray image data analysis: Initial validation testing through prostate cancer Gleason grading. Human Pathology, 2001, 32, 417-427.	2.0	53
261	PREDICTORS OF GLEASON PATTERN 4/5 PROSTATE CANCER ON PROSTATECTOMY SPECIMENS: CAN HIGH GRADE TUMOR BE PREDICTED PREOPERATIVELY?. Journal of Urology, 2001, 165, 114-118.	0.4	53
262	INTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 243-271.	22.4	53
263	Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer, 2011, 74, 118-123.	2.0	53
264	Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. Journal of Urology, 2009, 182, 2653-2658.	0.4	52
265	ERG rearrangement is present in a subset of transition zone prostatic tumors. Modern Pathology, 2010, 23, 1499-1506.	5.5	52
266	Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology, 2012, 60, 187-198.	2.9	52
267	10q23.3 loss of heterozygosity is higher inlymph node-positive (PT2-3,N+) versus lymph node-negative (PT2-3,N0) prostate cancer. Human Pathology, 2000, 31, 504-508.	2.0	51
268	Î±-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1418-1423.	2.5	51
269	Heterogeneous Nuclear Ribonucleoprotein K Is a Novel Regulator of Androgen Receptor Translation. Cancer Research, 2009, 69, 2210-2218.	0.9	51
270	Predisposition for <i>TMPRSS2-ERG</i> Fusion in Prostate Cancer by Variants in DNA Repair Genes. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3030-3035.	2.5	51

#	Article	IF	Citations
271	ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. Neoplasia, 2010, 12, 1031-IN22.	5.3	51
272	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	12.8	51
273	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
274	Visual cues as a surrogate for tactile feedback during roboticâ€assisted laparoscopic prostatectomy: posterolateral margin rates in 1340 consecutive patients. BJU International, 2010, 106, 528-536.	2.5	50
275	New Strategies in Prostate Cancer: Translating Genomics into the Clinic. Clinical Cancer Research, 2013, 19, 517-523.	7.0	50
276	Expression of the Platelet-Derived Growth Factor Receptor in Prostate Cancer and Treatment Implications with Tyrosine Kinase Inhibitors. Neoplasia, 2004, 6, 503-512.	5.3	49
277	Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer. Clinical Cancer Research, 2005, 11, 2237-2243.	7.0	49
278	Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology, 2005, 66, 930-934.	1.0	49
279	TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. Journal of Clinical Pathology, 2007, 60, 1185-1186.	2.0	49
280	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6686-6691.	7.1	49
281	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer, 2020, 1, 1082-1096.	13.2	49
282	Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformatics, 2002, 3, 26.	2.6	48
283	WHOLE MOUNTED RADICAL PROSTATECTOMY SPECIMENS DO NOT INCREASE DETECTION OF ADVERSE PATHOLOGICAL FEATURES. Journal of Urology, 2000, 164, 1583-1586.	0.4	47
284	Novel dual-color immunohistochemical methods for detecting ERGâ€"PTEN and ERGâ€"SPINK1 status in prostate carcinoma. Modern Pathology, 2013, 26, 835-848.	5.5	47
285	The Genomics of Prostate Cancer: emerging understanding with technologic advances. Modern Pathology, 2018, 31, 1-11.	5.5	47
286	Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes and Cancer, 2005, 44, 351-364.	2.8	46
287	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 471.	7.1	46
288	Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology, 2002, 59, 740-745.	1.0	45

#	Article	IF	Citations
289	Targeted therapy of cancer: new roles for pathologistsâ€"prostate cancer. Modern Pathology, 2008, 21, S44-S55.	5.5	45
290	Identification of Molecular Tumor Markers in Renal Cell Carcinomas with TFE3 Protein Expression by RNA Sequencing. Neoplasia, 2013, 15, 1231-1240.	5.3	45
291	Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors. Urology, 2000, 56, 721-725.	1.0	44
292	What Information are Urologists Extracting from Prostate Needle Biopsy Reports and What do They Need for Clinical Management of Prostate Cancer?. European Urology, 2005, 48, 911-915.	1.9	44
293	Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Human Pathology, 2007, 38, 1454-1462.	2.0	44
294	Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. International Journal of Cancer, 2008, 123, 569-576.	5.1	43
295	Non-coding genetic variation in cancer. Current Opinion in Systems Biology, 2017, 1, 9-15.	2.6	42
296	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer, 2018, 124, 1008-1015.	4.1	42
297	Prognostic factors in lymph node-positive prostate cancer. Urology, 2006, 67, 1016-1021.	1.0	41
298	Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate, 2006, 66, 1037-1043.	2.3	41
299	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	2.8	41
300	The Molecular Evolution of Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 506-513.	3.1	41
301	Evaluation of the interobserver reproducibility of gleason grading of prostatic adenocarcinoma using tissue microarrays. Human Pathology, 2003, 34, 444-449.	2.0	40
302	Whole Transcriptome Amplification for Gene Expression Profiling and Development of Molecular Archives. Neoplasia, 2006, 8, 153-162.	5.3	40
303	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology, 2020, 44, e15-e29.	3.7	40
304	Collagen XXIII Expression Is Associated with Prostate Cancer Recurrence and Distant Metastases. Clinical Cancer Research, 2007, 13, 2634-2642.	7.0	39
305	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3â€ERG</i> gene rearrangement and an unfavorable clinical course. International Journal of Cancer, 2013, 132, 807-812.	5.1	39
306	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology, 2022, 81, 426-438.	2.9	39

#	Article	IF	Citations
307	Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. Urology, 2002, 60, 276-280.	1.0	38
308	Molecular genetics of human prostate cancer. Modern Pathology, 2004, 17, 380-388.	5.5	37
309	Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochemical Pharmacology, 2009, 78, 1127-1138.	4.4	37
310	Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Cancer, 1997, 79, 2402-2408.	4.1	36
311	Variants at IRX4 as prostate cancer expression quantitative trait loci. European Journal of Human Genetics, 2014, 22, 558-563.	2.8	36
312	Abnormal prostate development in C3(1)-bcl-2 transgenic mice. , 1997, 32, 16-26.		35
313	Expression of Nuclear Antigen Ki-67 in Prostate Cancer Needle Biopsy and Radical Prostatectomy Specimens. Journal of the National Cancer Institute, 2000, 92, 1941-1942.	6.3	35
314	Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Laboratory Investigation, 2006, 86, 1099-1102.	3.7	35
315	Prostate cancer patientâ€derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. Journal of Pathology, 2021, 254, 543-555.	4.5	35
316	HITâ€™nDRIVE: Multi-driver Gene Prioritization Based on Hitting Time. Lecture Notes in Computer Science, 2014, , 293-306.	1.3	35
317	Identification of Two Molecular Groups of Seminomas by Using Expression and Tissue Microarrays. Clinical Cancer Research, 2005, 11, 5722-5729.	7.0	34
318	Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target. Molecular Cancer Therapeutics, 2012, 11, 775-783.	4.1	34
319	Somatic copy number alterations by whole-exome sequencing implicatesYWHAZandPTK2in castration-resistant prostate cancer. Journal of Pathology, 2013, 231, 505-516.	4.5	34
320	Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology, 2011, 58, 1028-1036.	2.9	33
321	Human bladder cancer diagnosis using multiphoton microscopy. , 2009, 7161, .		32
322	Genome-Wide Linkage Analysis of <i>TMPRSS2-ERG</i> Fusion in Familial Prostate Cancer. Cancer Research, 2009, 69, 640-646.	0.9	32
323	Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. Cell Reports, 2018, 22, 809-819.	6.4	32
324	Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends in Cancer, 2021, 7, 823-836.	7.4	32

#	Article	IF	Citations
325	Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule. Nature Medicine, 2005, 11, 95-101.	30.7	31
326	Next-generation Prostate Cancer Biobanking. Diagnostic Molecular Pathology, 2012, 21, 61-68.	2.1	31
327	Recurrent Prostate Cancer Genomic Alterations Predict Response to Brachytherapy Treatment. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 594-600.	2.5	31
328	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Modern Pathology, 2016, 29, 157-165.	5.5	31
329	Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome Biology, 2017, 18, 141.	8.8	31
330	The Lethal Clone in Prostate Cancer: Redefining the Index. European Urology, 2014, 66, 395-397.	1.9	30
331	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO Precision Oncology, 2017, 2017, 1-13.	3.0	30
332	Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. International Journal of Radiation Oncology Biology Physics, 1998, 41, 511-517.	0.8	29
333	Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen. World Journal of Urology, 2006, 24, 676-680.	2.2	29
334	Transforming growth factor Î²â€receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU International, 2011, 108, E23-8.	2.5	29
335	A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. Cell Reports, 2016, 15, 2348-2356.	6.4	29
336	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29
337	Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis. Cells, 2020, 9, 1496.	4.1	29
338	Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nature Communications, 2020, 11, 1987.	12.8	29
339	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. Journal of Clinical Investigation, 2017, 128, 381-386.	8.2	29
340	Usefulness of Basal Cell Cocktail (p63+34bE12) in the Diagnosis of Atypical Prostate Glandular Proliferations. American Journal of Clinical Pathology, 2004, 122, 517-523.	0.7	29
341	Understanding Disease Cell by Cell. Science, 2002, 296, 1329-1330.	12.6	28
342	Prostate cancer with Paneth cellâ€“like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Human Pathology, 2014, 45, 2136-2143.	2.0	28

#	Article	IF	Citations
343	Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Scientific Reports, 2016, 6, 24146.	3.3	28
344	Comprehensive Analysis of the Expression of the Metastasis-Associated Gene 1 in Human Neoplastic Tissue. Archives of Pathology and Laboratory Medicine, 2006, 130, 989-996.	2.5	28
345	Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer. Clinical Cancer Research, 2006, 12, 152-158.	7.0	27
346	An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 411-421.	2.0	27
347	Genomic rearrangements in prostate cancer. Current Opinion in Urology, 2015, 25, 71-76.	1.8	27
348	PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay. Developmental Cell, 2021, 56, 1661-1676.e10.	7.0	27
349	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	12.8	27
350	Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 20-24.	1.6	26
351	BPH Gene Expression Profile Associated to Prostate Gland Volume. Diagnostic Molecular Pathology, 2008, 17, 207-213.	2.1	26
352	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nature Communications, 2021, 12, 734.	12.8	26
353	Loss of Expression of Human Spectrin Src Homology Domain Binding Protein 1 is Associated with 10p Loss in Human Prostatic Adenocarcinoma. Neoplasia, 2001, 3, 99-104.	5.3	25
354	Impact of constitutional copy number variants on biological pathway evolution. BMC Evolutionary Biology, 2013, 13, 19.	3.2	25
355	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Journal of Physical Education and Sports Management, 2017, 3, a001487.	1.2	25
356	NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation. Cancer Discovery, 2021, 11, 2316-2333.	9.4	25
357	Molecular and Cytogenetic Characterization of Plexiform Leiomyomata Provide Further Evidence for Genetic Heterogeneity Underlying Uterine Fibroids. American Journal of Pathology, 2008, 172, 1403-1410.	3.8	24
358	In Situ Evidence of KRAS Amplification and Association With Increased p21 Levels in Nonâ€“Small Cell Lung Carcinoma. American Journal of Clinical Pathology, 2009, 132, 500-505.	0.7	24
359	Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Modern Pathology, 2009, 22, 933-939.	5.5	24
360	Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies. Journal of Translational Medicine, 2011, 9, 121.	4.4	24

#	Article	IF	Citations
361	Antibodyâ€independent targeted quantification of TMPRSS2â€ERG fusion protein products in prostate cancer. Molecular Oncology, 2014, 8, 1169-1180.	4.6	24
362	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
363	Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Advanced Materials, 2022, 34, e2100096.	21.0	24
364	Intertubular growth in pure seminomas: associations with poor prognostic parameters. Human Pathology, 2005, 36, 640-645.	2.0	23
365	An emerging role for cytopathology in precision oncology. Cancer Cytopathology, 2016, 124, 167-173.	2.4	23
366	Inherited determinants of early recurrent somatic mutations in prostate cancer. Nature Communications, 2017, 8, 48.	12.8	23
367	Giant malignant fibrous histiocytoma of the testis/spermatic cord: Psychologic and possible etilogic complications of unethical Nazi medical experimentation. Urology, 1996, 48, 939-943.	1.0	22
368	MAGI3â€"AKT3 fusion in breast cancer amended. Nature, 2015, 520, E11-E12.	27.8	22
369	Genomic Profiling of Hormone-NaÃ¯ve Lymph Node Metastases in Patients with Prostate Cancer. Neoplasia, 2006, 8, 1083-IN35.	5.3	21
370	Cancer-Specific Thresholds Adjust for Whole Exome Sequencingâ€"Based Tumor Mutational Burden Distribution. JCO Precision Oncology, 2019, 3, 1-12.	3.0	21
371	Common germline-somatic variant interactions in advanced urothelial cancer. Nature Communications, 2020, 11, 6195.	12.8	21
372	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	1.9	21
373	ETS rearrangements in prostate cancer. Asian Journal of Andrology, 2012, 14, 393-399.	1.6	21
374	Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes and Cancer, 2003, 37, 306-313.	2.8	20
375	Selective detection of histologically aggressive prostate cancer. Cancer, 2012, 118, 2651-2658.	4.1	20
376	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Neoplasia, 2019, 21, 389-400.	5.3	20
377	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 44.	5.4	20
378	Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance. Molecular Cancer Research, 2021, 19, 1398-1411.	3.4	20

#	Article	IF	Citations
379	THE ROLE OF THE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION ASSAY FOR PROSTATE-SPECIFIC ANTIGEN IN THE SELECTION OF PATIENTS FOR RADICAL PROSTATECTOMY. Urologic Clinics of North America, 1996, 23, 541-549.	1.8	19
380	Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 213-218.	1.6	19
381	Current Thoughts on the Role of the Androgen Receptor and Prostate Cancer Progression. Advances in Anatomic Pathology, 2005, 12, 265-270.	4.3	19
382	Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1682-1688.	2.5	19
383	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. Journal of Urology, 2014, 191, 830-841.	0.4	19
384	Prevalence and Location of Peripheral Nerve Found on Prostate Needle Biopsy. American Journal of Clinical Pathology, 2001, 115, 39-43.	0.7	18
385	Diagnosis of melanoma aspirates on ThinPrepÂ®: The University of Michigan experience. Diagnostic Cytopathology, 2002, 26, 334-339.	1.0	18
386	Prevention of Prostate Cancer with Finasteride. New England Journal of Medicine, 2003, 349, 1569-1572.	27.0	18
387	Molecular prostate cancer pathology: Current issues and achievements. Scandinavian Journal of Urology and Nephrology, 2005, 39, 82-93.	1.4	17
388	Tissue-preserving approach to extracting DNA from paraffin-embedded specimens using tissue microarray technology. Head and Neck, 2007, 29, 465-471.	2.0	17
389	G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nature Communications, 2021, 12, 6662.	12.8	17
390	Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology, 2005, 65, 528-532.	1.0	16
391	Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).. Journal of Clinical Oncology, 2016, 34, 5019-5019.	1.6	16
392	Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2001, 6, 53-55.	1.6	15
393	A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium. Journal of Urology, 2008, 179, 1243-1256.	0.4	15
394	Single Focus Prostate Cancer: Pathological Features and ERG Fusion Status. Journal of Urology, 2011, 185, 489-494.	0.4	15
395	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1716-1724.	1.6	15
396	A Comparative Study of ERG Status Assessment on DNA, mRNA, and Protein Levels Using Unique Samples from a Swedish Biopsy Cohort. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 136-141.	1.2	15

#	Article	IF	Citations
397	Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. BMC Genomics, 2015, 16, 247.	2.8	15
398	Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. Journal of Urology, 2017, 198, 42-49.	0.4	15
399	Inferior vena cavectomy for nonexcisable Wilms' tumor thrombus. Journal of Pediatric Surgery, 2001, 36, 526-529.	1.6	14
400	A Preliminary Study of JM-27: A Serum Marker That Can Specifically Identify Men With Symptomatic Benign Prostatic Hyperplasia. Journal of Urology, 2007, 177, 610-614.	0.4	14
401	Detection of TMPRSS2-ERG Fusion Gene Expression in Prostate Cancer Specimens by a Novel Assay Using Branched DNA. Urology, 2009, 74, 1156-1161.	1.0	14
402	Oncogenic transcription factors as master regulators of chromatin topology. Cell Cycle, 2012, 11, 3380-3383.	2.6	14
403	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16987-16996.	7.1	14
404	Prostate cancer hijacks the microenvironment. Nature Cell Biology, 2021, 23, 3-5.	10.3	14
405	MAXIMUM TUMOR DIMENSION PROVIDES A CLINICALLY USEFUL AND INDEPENDENTLY SIGNIFICANT MEASURE FOR PREDICTING PSA-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1999, , 241.	0.4	14
406	Effect of finasteride on risk of prostate cancer: How little we really know. Journal of Cellular Biochemistry, 2004, 91, 478-482.	2.6	13
407	USING MOLECULAR MARKERS TO PREDICT OUTCOME. Journal of Urology, 2004, 172, S18-21; discussion S21-2.	0.4	13
408	Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast. Human Pathology, 2016, 58, 54-61.	2.0	13
409	Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients. PLoS ONE, 2016, 11, e0147739.	2.5	13
410	Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. Journal of Pathology, 2022, 257, 274-284.	4.5	13
411	Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nature Communications, 2022, 13, 2400.	12.8	13
412	COMPLETE TRANSURETHRAL RESECTION OF BLADDER ENDOCERVICOSIS. Journal of Urology, 2001, 165, 524-524.	0.4	12
413	Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 249-251.	2.5	12
414	Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. Acta Neuropathologica Communications, 2020, 8, 80.	5.2	12

#	Article	IF	Citations
415	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 2022, 160, 24-60.	2.8	12
416	Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: a proposal based on patients treated with external beam radiotherapy. Urology, 1998, 51, 265-270.	1.0	11
417	The Genomics of Prostate Cancer: A Historic Perspective. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034942.	6.2	11
418	Comparative pathology of dog and human prostate cancer. Veterinary Medicine and Science, 2022, 8, 110-120.	1.6	11
419	Internet-based Profiler system as integrative framework to support translational research. BMC Bioinformatics, 2005, 6, 304.	2.6	10
420	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. Archives of Pathology and Laboratory Medicine, 2020, 144, 1535-1546.	2.5	10
421	Analysis of three-dimensional ultrasound Doppler for the detection of prostate cancer. Urology, 2001, 57, 1128-1132.	1.0	9
422	Constructing Tissue Microarrays for Research Use. Current Protocols in Human Genetics, 2003, 39, Unit 10.7.	3.5	9
423	Î±â€Methylacylâ€CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Followâ€up Study. Prostate, 2012, 72, 301-306.	2.3	9
424	Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. American Journal of Clinical Pathology, 2003, 120, 737-745.	0.7	9
425	On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures â€“ A Pilot Study. Anticancer Research, 2017, 37, 1569-1573.	1.1	9
426	V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application. Human Pathology, 2013, 44, 2282-2292.	2.0	8
427	Insights into the Mechanism of Organ-Specific Cancer Metastasis. Cancer Discovery, 2014, 4, 1262-1264.	9.4	8
428	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.6	8
429	Toward a prostate cancer precision medicine. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 73-74.	1.6	8
430	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic<i>TMPRSS2:ERG</i>fusion status. Human Molecular Genetics, 2016, 25, ddw349.	2.9	8
431	Clinical deployment of AI for prostate cancer diagnosis. The Lancet Digital Health, 2020, 2, e383-e384.	12.3	8
432	The evolving landscape of prostate cancer somatic mutations. Prostate, 2022, 82, .	2.3	8

#	Article	IF	Citations
433	Characterization of CD34-deficient myofibroblastomas of the breast. Breast Journal, 2018, 24, 55-61.	1.0	7
434	Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?. Cancer Discovery, 2018, 8, 682-685.	9.4	7
435	High-Density Tissue Microarray. American Journal of Surgical Pathology, 2002, 26, 1236-1237.	3.7	7
436	PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations. JCO Precision Oncology, 2021, 5, 1639-1649.	3.0	7
437	Towards a national strategy for digital pathology in Switzerland. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 647-652.	2.8	7
438	Mediastinal Seminoma in a Patient With Wiskott-Aldrich Syndrome. Journal of Pediatric Hematology/Oncology, 2002, 24, 672-676.	0.6	6
439	Gene-Expression Profiles in Hereditary Breast Cancer. Advances in Anatomic Pathology, 2002, 9, 1-6.	4.3	6
440	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	27.8	6
441	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	1.6	6
442	Transcriptional regulation and prostate cancer risk loci.. Journal of Clinical Oncology, 2013, 31, 1554-1554.	1.6	6
443	Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI Insight, 2022, 7, .	5.0	6
444	Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in <i>CCDC6-RET</i>â€“rearranged thyroid cancer. Journal of Experimental Medicine, 2022, 219, .	8.5	6
445	Neuroendocrine Prostate Cancer. , 2013, , 277-282.		5
446	Molecular Archeology: Unearthing Androgen-Induced Structural Rearrangements in Prostate Cancer Genomes. Cancer Cell, 2013, 23, 133-135.	16.8	5
447	Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Journal of Translational Medicine, 2017, 15, 175.	4.4	5
448	Rapid autopsy of a patient with recurrent anaplastic ependymoma. Palliative and Supportive Care, 2018, 16, 238-242.	1.0	5
449	Sequence of events in prostate cancer. Nature, 2018, 560, 557-559.	27.8	5
450	Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component. Veterinary and Comparative Oncology, 2022, 20, 38-49.	1.8	5

#	Article	IF	Citations
451	A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2013, 31, TPS5096-TPS5096.	1.6	5
452	Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2014, 32, 177-177.	1.6	5
453	A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients. Molecular Cancer Research, 2021, , molcanres.0255.2021.	3.4	5
454	FOURTH INTERNATIONAL CONFERENCE ON INNOVATIONS AND CHALLENGES IN PROSTATE CANCER: PREVENTION, DETECTION AND TREATMENT. Journal of Urology, 2004, 172, S3-5.	0.4	4
455	Platelet-Derived Growth Factor Receptor Inhibitor Imatinib Mesylate and Docetaxel: A Modular Phase I Trial in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 1332-1333.	1.6	4
456	Response to â€˜TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomasâ€™. Modern Pathology, 2009, 22, 1398-1399.	5.5	4
457	Molecular Characterization of Prostate Cancer Following Androgen Deprivation: The Devil in the Details. European Urology, 2014, 66, 40-41.	1.9	4
458	Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 786-793.	3.9	4
459	Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.. Journal of Clinical Oncology, 2015, 33, 197-197.	1.6	4
460	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
461	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer, 2022, 4, .	3.1	4
462	Benign positive margins after radical prostatectomy means a poor prognosisâ€”con. Urology, 2005, 65, 221-223.	1.0	3
463	Partially circumventing peripheral tolerance for oncogeneâ€specific prostate cancer immunotherapy. Prostate, 2008, 68, 715-727.	2.3	3
464	Prostate Cancer Research at the Crossroads. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a036277.	6.2	3
465	SETting Up for Epigenetic Regulation of Advanced Prostate Cancer. Cancer Cell, 2020, 38, 309-311.	16.8	3
466	Defining a molecular subclass of treatment resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5004-5004.	1.6	3
467	Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing.. Journal of Clinical Oncology, 2016, 34, 354-354.	1.6	3
468	Bringing Pathobiology into Focus. Laboratory Investigation, 2006, 86, 632-632.	3.7	2

#	Article	IF	Citations
469	Letter to the Editor. Modern Pathology, 2008, 21, 1056-1056.	5.5	2
470	Turkey Must End Violent Response to Protests. Science, 2013, 341, 236-236.	12.6	2
471	Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. , 2000, 43, 278.		2
472	Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5009-5009.	1.6	2
473	Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.. Journal of Clinical Oncology, 2018, 36, 5064-5064.	1.6	2
474	Integrative molecular profiling challenges robustness of prognostic signature scores in multifocal prostate cancer.. Journal of Clinical Oncology, 2018, 36, 96-96.	1.6	2
475	Re: Stoehr <i>et al.</i> Lack of evidence for frequent <i>MED12</i> p.L1224F mutation in prostate tumours from Caucasian patients. <i>J Pathol</i> 2013; 230: 453-456. Journal of Pathology, 2013, 231, 271-271.	4.5	1
476	Clinical hallmarks in whole cancer genomes. Nature Reviews Clinical Oncology, 2017, 14, 265-266.	27.6	1
477	Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. European Urology, 2017, 71, 301.	1.9	1
478	GRAM: A GeneRAlized Model to predict the molecular effect of a non-coding variant in a cell-type specific manner. PLoS Genetics, 2019, 15, e1007860.	3.5	1
479	Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, 4513-4513.	1.6	1
480	Upper tract urothelial carcinoma is non-basal and T-cell depleted.. Journal of Clinical Oncology, 2018, 36, 4525-4525.	1.6	1
481	Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2014, 32, 290-290.	1.6	1
482	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. Journal of Clinical Oncology, 2015, 33, 158-158.	1.6	1
483	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. Blood, 2018, 132, 1435-1435.	1.4	1
484	INTEGRATION OFERGGENE MAPPING AND GENE-EXPRESSION PROFILING IDENTIFIES DISTINCT CATEGORIES OF HUMAN PROSTATE CANCER. BJU International, 2009, 103, 1293-1293.	2.5	0
485	Identifying an ERG-positive Subclass with Clinical Progression Using Expression Profiling. European Urology, 2013, 64, 951-952.	1.9	0
486	Genomics and Epigenomics of Prostate Cancer. , 2015, , 149-170.		0

#	Article	IF	Citations
487	High-Density Tissue Microarray. American Journal of Surgical Pathology, 2002, 26, 1237-1238.	3.7	0
488	Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2012, 30, 120-120.	1.6	0
489	Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. Journal of Clinical Oncology, 2012, 30, 110-110.	1.6	0
490	Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.. Journal of Clinical Oncology, 2012, 30, 4649-4649.	1.6	0
491	Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing. Blood, 2012, 120, 899-899.	1.4	0
492	Development of novel metastatic prostate cancer cell lines by â€œorganoidâ€•in vitro culture technology.. Journal of Clinical Oncology, 2014, 32, 33-33.	1.6	0
493	Clonal heterogeneity in platinum-resistant metastatic urothelial cancer.. Journal of Clinical Oncology, 2015, 33, 290-290.	1.6	0
494	Abstract PR08: The N-Myc transcriptional program driving the neuroendocrine prostate cancer phenotype. , 2015, , .		0
495	Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2016, 34, 379-379.	1.6	0
496	Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 299-299.	1.6	0
497	The long tail of significantly mutated genes in prostate cancer.. Journal of Clinical Oncology, 2017, 35, 131-131.	1.6	0
498	Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.. Journal of Clinical Oncology, 2018, 36, 218-218.	1.6	0